AstraZeneca

(PRESS RELEASE) CAMBRIDGE, 2-Nov-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced fully funded postdoctoral research positions for the six winners at its R&D Postdoctoral Challenge announced earlier this year. The research positions … Read the full press release →

(PRESSEMITTEILUNG) CAMBRIDGE, 2-Nov-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), ein britisch-schwedisches multinationales Unternehmen Pharma- und Biotechnologieunternehmen, hat voll finanzierte Postdoktoranden-Forschungsstellen für die sechs Gewinner in seinem R&D Postdoctoral Challenge früher in diesem Jahr angekündigt. Die Forschungspositionen werden für zwei Jahre … Read the full press release →

El desafío tiene como objetivo ayudar al descubrimiento de avances transformadores en las áreas de enfermedades centrales de AstraZeneca. Las propuestas exitosas asegurarán puestos de investigación posdoctorales totalmente financiados (COMUNICADO DE PRENSA) CAMBRIDGE, 17-Mar-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), … Read the full press release →

The challenge aims at helping the discovery of transformative breakthroughs across AstraZeneca’s core disease areas Successful proposals will secure fully funded postdoctoral research positions (PRESS RELEASE) CAMBRIDGE, 17-Mar-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology … Read the full press release →

(COMMUNIQUÉ DE PRESSE) CAMBRIDGE, 16-Feb-2022 — /EuropaWire/ — AstraZeneca (LON : AZN), une multinationale pharmaceutique et biotechnologique anglo-suédoise , a annoncé l’approbation par l’Union européenne (UE) de son médicament Saphnelo (anifrolumab) en tant que traitement d’appoint pour le traitement des patients … Read the full press release →

(PRESS RELEASE) CAMBRIDGE, 16-Feb-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced an European Union (EU) approval for its Saphnelo (anifrolumab) medicine as an add-on therapy for the treatment of adult patients with … Read the full press release →

Tony Wood übernimmt im August 2022 die volle Verantwortung für die F&E von GSK Hal Barron wechselt im August 2022 vom CSO zu einem GSK Non-Executive Director mit zusätzlichen Verantwortlichkeiten zur Unterstützung von Forschung und Entwicklung (PRESSEMITTEILUNG) LONDON, 19-Jan-2022 — … Read the full press release →

Tony Wood to assume full accountability for GSK R&D in August 2022 Hal Barron to transition in August 2022 from CSO to a GSK Non-Executive Director with additional responsibilities to support R&D (PRESS RELEASE) LONDON, 19-Jan-2022 — /EuropaWire/ — GlaxoSmithKline … Read the full press release →

Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition (PRESS RELEASE) CAMBRIDGE, 7-Jan-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced … Read the full press release →

(PRESS RELEASE) CAMBRIDGE, 5-Jan-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the completion of the transfer of its global rights to Eklira (aclidinium bromide), popular as Tudorza in the US, and Duaklir … Read the full press release →